Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Core Insights - Barinthus Bio is prioritizing the development of VTP-300 for chronic Hepatitis B (CHB) and VTP-1000 for celiac disease, which is expected to lead to a workforce reduction of approximately 25% and extend the cash runway into the second quarter of 2026 [1][8]. Group 1: Pipeline Development - The decision to prioritize VTP-300 and VTP-1000 follows positive interim data from ongoing Phase 2 clinical trials, indicating VTP-300's potential to significantly reduce and maintain Hepatitis B surface antigen (HBsAg) levels [2][3]. - VTP-1000 aims to balance the immune response in celiac disease by inducing gluten-specific T regulatory cells while reducing gluten-specific T effector cell responses, with a Phase 1 clinical trial expected to start in Q3 2024 [2][4]. Group 2: Company Strategy - The restructuring aligns resources with the streamlined pipeline, focusing on immunotherapies to transform patients' lives, particularly in chronic infectious diseases and autoimmunity [3][4]. - The company emphasizes its commitment to advancing its promising pipeline and is optimistic about upcoming clinical milestones in both HBV and celiac disease programs [3][4].